In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Titan Pharmaceuticals Inc.

www.titanpharm.com

Latest From Titan Pharmaceuticals Inc.

US FDA Must Explain How It Defines ‘Innovation’ In Awarding Hatch/Waxman Exclusivity, Court Says

Agency's decision that Indivior’s Sublocade blocked Braeburn’s long-acting buprenorphine formulation Brixadi lacked ‘substantive guideposts’ in how innovation is defined for purposes of deciding scope of three-year exclusivity, US judge says.

Legal Issues FDA

Molteni Farmaceutici Plans For EU Entry Of Titan’s Six-Month Buprenorphine Implant

Molteni Farmaceutici/Titan’s Sixmo, the first six-month buprenorphine implant just approved for EU marketing, could be a valued option for a sizeable number of patients.

 

Approvals Europe

Keeping Track: An RMAT, Two QIDPs, And Some Bad News Too

The latest drug development news and highlights from our FDA Performance Tracker.

Drug Review Regulation

Indivior To Appeal US Suboxone Setback, Flags Follow-On Drug RBP-6000

Shares in Indivior slid nearly 40% on news of a US court ruling which raises chances its key opioid addiction treatment may face generic competition sooner than expected.

Business Strategies Companies
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
    • Implantable Devices
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Titan Pharmaceuticals Inc.
  • Senior Management
  • Sunil Bhonsle, Pres.
    Katherine L Beebe, PhD, EVP & Chief Dev. Officer
  • Contact Info
  • Titan Pharmaceuticals Inc.
    Phone: (650) 244-4990
    400 Oyster Point Blvd.
    Ste. 505
    S. San Francisco, CA 94080-1921
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register